A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

"Unlike existing drugs for depression, esketamine does not directly involve serotonin, norepinephrine, or dopamine reuptake," says Dr. Sheline. But it's not entirely known why Spravato works in ...

MDD has a high economic burden, with nearly half of it attributable to treatment-resistant depression (TRD). 3,4,5 "Treatment-resistant depression can be very complicated, especially for patients ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...